Prevencio Receives FDA Breakthrough Device Designation for HART CADhs

Prevencio has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its HART CADhs® test. This designation recognizes HART CADhs as an innovative technology for identifying obstructive coronary artery disease (CAD), a condition responsible for significant morbidity and mortality.